Swiss drug giant Novartis (NVS) said Monday that its oral multiple-sclerosis drug Gilenya failed a late-stage clinical trial for a particularly virulent form of the disease. The company said Gilenya didn’t do better than a placebo in patients with progressive primary multiple sclerosis (PPMS). Unlike the more common relapsing-remitting form of the disease, PPMS brings neurologic decline from the outset but with fewer visible symptoms, often
Wall Street rewarded Novartis and Regeneron Tuesday for presentations at a cardiology conference over the weekend, with Novartis’ heart-failure drug hailed as a potential game-changer. At the European Society of Cardiology (ESC) Congress in Barcelona, Novartis (NVS) revealed results of a phase three trial of patients suffering heart failure with reduced ejection fraction. (Ejection fraction is a measure of how much blood a heart
Swiss pharma giant Novartis (NVS) was up nearly 4% to a new high above 93 in early trading on the stock market today after it released positive clinical-trial data on its heart-failure drug over the weekend. At least one analyst says that the drug could top $6 billion in annual sales. At the European Society of Cardiology Congress in Barcelona, Novartis presented results of a study of patients with heart failure with reduced ejection fraction,